Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- BIKEN to Stop Shipment of Japanese Encephalitis Vaccine on Bacterial Contamination
January 18, 2021
- Vietnam’s Ha Tay Now an ASKA Group Company
January 18, 2021
- Janssen Files Imbruvica for Post-Transplant GVHD in Japan
January 18, 2021
- Taiho Sets Up Stand-Alone Subsidiary in Switzerland
January 18, 2021
- Chiome Licenses Anti-TROP-2 Antibodies to China Firm
January 18, 2021
- Zeria, Astellas Wind Up Copromotion for Acofide
January 18, 2021
- Only 1/338th the Number of Flu Patients in December 2020 vs December 2019: Survey
January 18, 2021
- Sawai Continues Shipment Control, Supply Suspensions for 5 Drugs on COVID-19, Recalls by Peers
January 18, 2021
- Towa, Nissin to Recall Dipyridamole Over PMD Law Violation by API Warehouse Operator
January 18, 2021
- Kolon Ordered Payment to Mitsubishi Tanabe over Cell Therapy License Deal
January 15, 2021
- Genmab Set for Stand-Alone Drug Development, Biz in Japan
January 15, 2021
- Kaken to Codevelop Novel Multi-Specific Antibody with Swiss Biotech
January 15, 2021
- Daiichi Sankyo’s DMD Therapy Shows Efficacy in Several Patients in PI/II
January 14, 2021
- Nichi-Iko Announces Yet Another Recall, 38 Products Added to Bring Total to 75
January 14, 2021
- EA Pharma/Kissei Prepping to File Ulcerative Colitis Drug on Positive Japan PIII
January 14, 2021
- More than 90% of Patients Will Visit Doctors as Planned despite Emergency Declared: Survey
January 14, 2021
- Astellas Launches Joint Research on Molecular-Targeted Radiotherapies with US Biopharma
January 14, 2021
- Taiho Licenses SHP2 Drug Discovery Program to US Merck
January 14, 2021
- Chugai Links Up with IBM to Go Digital in Manufacturing
January 14, 2021
- Sosei Pairs Up with UK’s AI-Powered Drug Discovery Firm
January 13, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…